Table of Contents
Direct oral anticoagulants (DOACs) have become increasingly popular for the management of various thromboembolic disorders due to their ease of use and favorable safety profiles. However, their perioperative management presents unique challenges that require careful planning to minimize bleeding risks while preventing thrombotic events.
Understanding DOACs in Perioperative Settings
DOACs, including dabigatran, rivaroxaban, apixaban, and edoxaban, act by directly inhibiting specific clotting factors. Their predictable pharmacokinetics often eliminate the need for routine monitoring, but this characteristic complicates perioperative management, especially regarding timing of discontinuation and resumption.
Preoperative Considerations
Effective perioperative management begins with assessing the patient’s thrombotic risk and bleeding risk. Factors influencing decision-making include the type of surgery, patient comorbidities, and the specific DOAC used.
Assessing Thrombotic and Bleeding Risks
High thrombotic risk patients, such as those with recent venous thromboembolism or mechanical heart valves, require careful balancing of bleeding risks. Surgical procedures with high bleeding risk necessitate discontinuation of DOACs well in advance.
Timing of Discontinuation
- Dabigatran: 48 hours before high-risk procedures in patients with normal renal function.
- Rivaroxaban, Apixaban, Edoxaban: 24-48 hours prior, depending on renal function and bleeding risk.
Renal function significantly influences the timing of discontinuation, especially for dabigatran, which is primarily renally excreted.
Perioperative Management Strategies
Strategies involve stopping DOACs at appropriate times, considering bridging in select cases, and planning for perioperative anticoagulation resumption.
Bridging Therapy
In most cases, bridging with heparin is not necessary due to the rapid onset and offset of DOACs. However, in high thrombotic risk patients, some clinicians may consider bridging with low molecular weight heparin (LMWH).
Managing Bleeding Risks
Intraoperative and postoperative bleeding risks are minimized by adhering to the timing of DOAC discontinuation and employing meticulous surgical techniques. Availability of reversal agents, such as idarucizumab for dabigatran and andexanet alfa for factor Xa inhibitors, is essential in managing bleeding complications.
Postoperative Resumption
Resuming DOAC therapy depends on achieving hemostasis and the patient’s bleeding risk profile. Typically, DOACs are restarted 24-72 hours after surgery, with timing individualized based on clinical judgment.
Special Considerations
Certain patient populations require tailored approaches:
- Renal impairment: Adjust timing and dosing accordingly.
- Elderly patients: Increased bleeding risk necessitates careful assessment.
- Emergency surgeries: May require rapid reversal of anticoagulation.
Conclusion
Perioperative management of DOACs demands a comprehensive understanding of pharmacology, patient-specific risks, and surgical factors. Collaboration among clinicians, including surgeons, anesthesiologists, and hematologists, is vital to optimize outcomes and ensure patient safety.